Drug detection test kit G09044

clinicalserumplasma

RIDASCREEN® Anti-ADM Antibodies is an enzyme linked immunoassay intended for the quantitative determination of antibodies to adalimumab (ATA) in human serum and plasma. Key features CE-marked versions of the ELISA tests of KU Leuven Highly specific antibodies Validated in clinical trials Validated on automated ELISA readers (e.g. DSX®) Therapeutic Drug Monitoring Adalimumab (ADM) is an human antibody that targets the pro-inflammatory cytokine TNF-alpha. The introduction of adalimumab has revolutionized the treatment of chronic inflammatory diseases like inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and spondyloarthritis. It has been shown that adalimumab can induce deep remission and improve the patient’s quality of life. Some patients do not respond to adalimumab therapy upon induction (primary non-responders), while others lose response over time (secondary non-responders). Immunogenicity Secondary loss of response is often due to the development of anti-adalimumab antibodies (ATA), because of the immunogenic character of the drug. ATA can develop in any patient undergoing adalimumab therapy and are primarily neutralizing the activity of adalimumab through immunocomplex formation. In addition, these immunocomplexes are rapidly cleared from the system. Analytically, they are responsible for subtherapeutic adalimumab concentrations. Therefore, in the case of very low trough concentrations of adalimumab (< 1 μg/ml), subsequent measurement of ATA may be helpful to determine the optimal treatment strategy.